SCHEMBL1743192

SCHEMBL1743192

Clc1ccc(-c2ccc3ccccc3n2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.54
RAB9A P51151 12/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
AR P10275 2/20 0.54
KDM4E B2RXH2 8/20 0.53
SMN1; SMN2 Q16637 8/20 0.53
ALDH1A1 P00352 5/20 0.53
MAPT P10636 4/20 0.53
CYP3A4 P08684 2/20 0.53
GMNN O75496 1/20 0.53
TP53 P04637 1/20 0.53
PKM P14618 1/20 0.53
HPGD P15428 1/20 0.53
THPO P40225 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483733 0.79 RAB9A (0.64) NPC1RAB9AMEN1KMT2AAR
SCHEMBL2164450 0.79 RAB9A (0.54) NPC1RAB9AMEN1KMT2AAR
SCHEMBL12112870 0.79 RAB9A (0.80) NPC1RAB9AMEN1KMT2AAR
SCHEMBL708675 0.78 NPC1 (0.67) NPC1RAB9AMEN1KMT2AAR
SCHEMBL30644241 0.78 NPC1 (0.67) NPC1RAB9AMEN1KMT2AAR
SCHEMBL26826802 0.77 NPC1 (0.65) NPC1RAB9AMEN1KMT2AAR
SCHEMBL2164493 0.76 NCF1 (0.59) NPC1RAB9AMEN1KMT2AAR
SCHEMBL12970409 0.76 RAB9A (0.50) NPC1RAB9AMEN1KMT2AAR
SCHEMBL21974426 0.76 NCF1 (0.61) NPC1RAB9AMEN1KMT2AAR
SCHEMBL26613610 0.76 NPC1 (0.62) NPC1RAB9AMEN1KMT2AAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
CN-101218206-A Histamine H3 receptor antagonists NOVO NORDISK AS (DK) 2008-07-09 CN disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 NPC1 2646/4885RAB9A 4607/4885MEN1 862/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 NPC1 2646/4885RAB9A 4607/4885MEN1 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.